Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

Apellis, Sobi enter territorial deal for C3 inhibitor
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) granted Swedish Orphan Biovitrum AB (SSE:SOBI) exclusive ex-U.S. rights to systemic therapy pegcetacoplan (APL-2), an inhibitor of C3. The partners will jointly develop the therapy for hematology, nephrology and neurological indications including paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G) and amyotrophic lateral sclerosis (ALS). Apellis will receive $250 million up front and $80 million in reimbursements. It’s also eligible for $915 million in milestones.

Simcere slips in Hong Kong debut
Shares of Simcere Pharmaceutical Group Ltd. (HKEX:2096) sank 20% to HK$10.98 on Tuesday after the company raised HK$3.6 billion ($460.4 million) through the sale of 260.6 million shares at HK$13.70 in its IPO.  The deal came at a valuation of about $4.6 billion. Once primarily a generics company, Simcere is increasingly focusing on innovative therapies in fields such as oncology and immunology; it traded on the NYSE before a 2013 take-private deal...